Lysa
19 June 2018
LYSA’s RELEVANCE Trial in the Media
Return on the presentation of Franck Morschhauser, from Claude Huriez Hospital (Lille, France), president of the LYSA scientific committee, on the interim results obtained for the phase III clinical trial RELEVANCE.
Please, discover the press release on this study, published on the website of ASHand the video made by ecancer!
Reference: Franck Morschhauser et al. Relevance : Phase III Efficacity and safety study of lenalidomide plus rituximab (R2) versus rituximab plus chemotherapy, followed by rituximab, in previously untreated follicular lymphoma.
